118 related articles for article (PubMed ID: 25083915)
1. Energy restriction mimetic agents to target cancer cells: comparison between 2-deoxyglucose and thiazolidinediones.
Kuntz S; Mazerbourg S; Boisbrun M; Cerella C; Diederich M; Grillier-Vuissoz I; Flament S
Biochem Pharmacol; 2014 Nov; 92(1):102-11. PubMed ID: 25083915
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects of energy restriction-mimetic agents: thiazolidinediones.
Omar HA; Salama SA; Arafa el-SA; Weng JR
Biol Chem; 2013 Jul; 394(7):865-70. PubMed ID: 23612598
[TBL] [Abstract][Full Text] [Related]
3. Energy restriction as an antitumor target of thiazolidinediones.
Wei S; Kulp SK; Chen CS
J Biol Chem; 2010 Mar; 285(13):9780-9791. PubMed ID: 20093366
[TBL] [Abstract][Full Text] [Related]
4. Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones.
Weng JR; Chen CY; Pinzone JJ; Ringel MD; Chen CS
Endocr Relat Cancer; 2006 Jun; 13(2):401-13. PubMed ID: 16728570
[TBL] [Abstract][Full Text] [Related]
5. Effects of Thiazolidinediones on metabolism and cancer: Relative influence of PPARγ and IGF-1 signaling.
Mughal A; Kumar D; Vikram A
Eur J Pharmacol; 2015 Dec; 768():217-25. PubMed ID: 26542126
[TBL] [Abstract][Full Text] [Related]
6. [Anti-cancer action by PPARgamma ligand].
Okumura T
Nihon Rinsho; 2010 Feb; 68(2):267-72. PubMed ID: 20158095
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy and chemoprevention by thiazolidinediones.
Fröhlich E; Wahl R
Biomed Res Int; 2015; 2015():845340. PubMed ID: 25866814
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator-activating receptors: a new way to treat melanoma?
Schadendorf D
J Invest Dermatol; 2009 May; 129(5):1061-3. PubMed ID: 19369932
[TBL] [Abstract][Full Text] [Related]
9. The potential of antidiabetic thiazolidinediones for anticancer therapy.
Galli A; Mello T; Ceni E; Surrenti E; Surrenti C
Expert Opin Investig Drugs; 2006 Sep; 15(9):1039-49. PubMed ID: 16916271
[TBL] [Abstract][Full Text] [Related]
10. Chemical Synthesis, Mechanism of Action and Anticancer Potential of Medicinally Important Thiazolidin-2,4-dione Derivatives: A Review.
Kumar H; Deep A; Marwaha RK
Mini Rev Med Chem; 2019; 19(18):1474-1516. PubMed ID: 31092179
[TBL] [Abstract][Full Text] [Related]
11. A new dawn for the use of thiazolidinediones in cancer therapy.
Joshi H; Pal T; Ramaa CS
Expert Opin Investig Drugs; 2014 Apr; 23(4):501-10. PubMed ID: 24597633
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines.
Yang FG; Zhang ZW; Xin DQ; Shi CJ; Wu JP; Guo YL; Guan YF
Acta Pharmacol Sin; 2005 Jun; 26(6):753-61. PubMed ID: 15916743
[TBL] [Abstract][Full Text] [Related]
13. Cell cycle synchronisation using thiazolidinediones affects cellular glucose metabolism and enhances the therapeutic effect of 2-deoxyglucose in colon cancer.
Yoon JK; Byeon HE; Ko SA; Park BN; An YS; Lee HY; Lee YW; Lee SJ
Sci Rep; 2020 Mar; 10(1):4713. PubMed ID: 32170185
[TBL] [Abstract][Full Text] [Related]
14. Thiazolidinediones inhibit hepatocarcinogenesis in hepatitis B virus-transgenic mice by peroxisome proliferator-activated receptor gamma-independent regulation of nucleophosmin.
Galli A; Ceni E; Mello T; Polvani S; Tarocchi M; Buccoliero F; Lisi F; Cioni L; Ottanelli B; Foresta V; Mastrobuoni G; Moneti G; Pieraccini G; Surrenti C; Milani S
Hepatology; 2010 Aug; 52(2):493-505. PubMed ID: 20683949
[TBL] [Abstract][Full Text] [Related]
15. Thiazolidinediones/PPARγ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer.
Mansour M; Schwartz D; Judd R; Akingbemi B; Braden T; Morrison E; Dennis J; Bartol F; Hazi A; Napier I; Abdel-Mageed AB
Int J Oncol; 2011 Feb; 38(2):537-46. PubMed ID: 21170507
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor-gamma antagonists exhibit potent antiproliferative effects versus many hematopoietic and epithelial cancer cell lines.
Burton JD; Castillo ME; Goldenberg DM; Blumenthal RD
Anticancer Drugs; 2007 Jun; 18(5):525-34. PubMed ID: 17414621
[TBL] [Abstract][Full Text] [Related]
17. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists.
Grommes C; Landreth GE; Heneka MT
Lancet Oncol; 2004 Jul; 5(7):419-29. PubMed ID: 15231248
[TBL] [Abstract][Full Text] [Related]
18. 2-Deoxy-D-glucose targeting of glucose metabolism in cancer cells as a potential therapy.
Zhang D; Li J; Wang F; Hu J; Wang S; Sun Y
Cancer Lett; 2014 Dec; 355(2):176-83. PubMed ID: 25218591
[TBL] [Abstract][Full Text] [Related]
19. Topical treatment with thiazolidinediones, activators of peroxisome proliferator-activated receptor-gamma, normalizes epidermal homeostasis in a murine hyperproliferative disease model.
Demerjian M; Man MQ; Choi EH; Brown BE; Crumrine D; Chang S; Mauro T; Elias PM; Feingold KR
Exp Dermatol; 2006 Mar; 15(3):154-60. PubMed ID: 16480422
[TBL] [Abstract][Full Text] [Related]
20. Rosiglitazone induces autophagy in H295R and cell cycle deregulation in SW13 adrenocortical cancer cells.
Cerquetti L; Sampaoli C; Amendola D; Bucci B; Masuelli L; Marchese R; Misiti S; De Venanzi A; Poggi M; Toscano V; Stigliano A
Exp Cell Res; 2011 Jun; 317(10):1397-410. PubMed ID: 21376716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
